Cichoric Acid

Cichoric Acid

SCHEMBL29349701

O=C(/C=C/c1ccc(O)c(O)c1)O[C@@H](C(=O)O)[C@@H](OC(=O)/C=C/c1ccc(O)c(O)c1)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 7/20 1.00
TDP1 Q9NUW8 6/20 1.00
ALOX15 P16050 3/20 1.00
TP53 P04637 2/20 1.00
SRC P12931 2/20 0.84
APP P05067 8/20 0.65
KDM4E B2RXH2 6/20 0.65
TTR P02766 6/20 0.65
MAPT P10636 5/20 0.65
HPGD P15428 4/20 0.65
AKR1B1 P15121 4/20 0.65
POLB P06746 3/20 0.65
GAA P10253 3/20 0.65
RECQL P46063 2/20 0.65
MMP1 P03956 2/20 0.65
THRB P10828 2/20 0.65
APEX1 P27695 2/20 0.65
CYP1A2 P05177 2/20 0.65
LCK P06239 2/20 0.65
FYN P06241 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chicoric Acid SCHEMBL13772650 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL30518333 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL964775 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL30995918 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL730803 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Cichoric Acid SCHEMBL29385936 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL963407 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL961606 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL21176639 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Cichoric Acid SCHEMBL15532218 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4701437-A2 PHARMACEUTICAL COMPOSITION TO SUPPORT THE IMMUNE SYSTEM BEFORE AND DURING UPPER RESPIRATORY TRACT INFECTIONS Aronpharma SP. Z O. O (PL) 2026-03-04 EP claimed
EP-2603098-B1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER FIRMENICH INCORPORATED (US) 2025-08-06 EP claimed
US-20250009892-A1 DELIVERY SYSTEMS AND METHODS FOR REACTIVE HYDROXYL-CONTAINING COMPOUNDS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2025-01-09 US claimed
WO-2024225922-A2 PHARMACEUTICAL COMPOSITION TO SUPPORT THE IMMUNE SYSTEM BEFORE AND DURING UPPER RESPIRATORY TRACT INFECTIONS ARONPHARMA SP. Z O. O. (PL) 2024-10-31 WO claimed
US-20240309410-A1 AN ENZYMATIC PROCESS FOR PRODUCING HYDROXYCINNAMIC ACID AMIDES (HCAA) ANALYTICON DISCOVERY GMBH (DE) 2024-09-19 US claimed
EP-4431611-A1 AN ENZYMATIC PROCESS FOR PRODUCING HYDROXYCINNAMIC ACID AMIDES (HCAA) Analyticon Discovery GmbH (DE) 2024-09-18 EP claimed
EP-3823464-B1 METHOD FOR REMOVING IMPURITIES FROM VEGETABLE PREPARATIONS FRUTAROM SCHWEIZ AG (CH) 2024-08-14 EP claimed
CN-113845422-B Process for preparing L-chicoric acid from Echinacea purpurea in batches and application thereof 山东中医药大学 2024-01-30 CN claimed
US-11732136-B2 Hydroxycinnamic acid-derived crosslinkers INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2023-08-22 US claimed
US-11701400-B2 Steviol glycoside compositions with reduced surface tension CARGILL, INCORPORATED (US) 2023-07-18 US claimed
US-11571407-B2 Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis BCN PEPTIDES, S.A. (ES) 2023-02-07 US claimed
WO-2023273955-A1 METHOD FOR PREPARING NANOFIBER MEMBRANE COMPOSITE FABRIC 南通大学 2023-01-05 WO claimed
US-20220242809-A1 METHODS FOR ISOLATING ESSENTIAL OILS, PHYTOCHEMICALS AND PHARMACEUTICALLY ACTIVE COMPONENTS FROM BIOMASS AND RECONSTITUTING SYNTHETIC FORMULATIONS COMPRISING SAME ATLAS HEMP COMPANY LLC (US) 2022-08-04 US claimed
WO-2022153155-A1 HYDROXYCINNAMIC ACID-DERIVED CROSSLINKING DIMERS INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2022-07-21 WO claimed
WO-2022153156-A1 HYDROXYCINNAMIC ACID-DERIVED CROSSLINKERS INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2022-07-21 WO claimed
US-20220220280-A1 HYDROXYCINNAMIC ACID-DERIVED CROSSLINKING DIMERS INTERNATIONAL BUSINESS MACHINES CORPORATION 2022-07-14 US claimed
US-20220220310-A1 HYDROXYCINNAMIC ACID-DERIVED CROSSLINKERS INTERNATIONAL BUSINESS MACHINES CORPORATION 2022-07-14 US claimed
WO-2022141375-A1 COMPOSITION FOR CARING FOR KERTATIN MATERIALS L'OREAL (FR) 2022-07-07 WO claimed
US-11261477-B2 Glycosylation modification of bioactive compounds and drugs by plant glycosyltransferases (UGTs) UNIVERSITY OF NORTH TEXAS (US) 2022-03-01 US claimed
EP-3941188-A1 PHYTOCOMPLEX AND EXTRACT OF A MERISTEMATIC CELL LINE SELECTED FROM ECHINACEA PURPUREA Aethera Biotech S.r.l. (IT) 2022-01-26 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11571407-B2 Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis GBA1, GAA, GBA3 HSD17B10 1472/4885TDP1 876/4885ALOX15 4056/4885
US-11701400-B2 Steviol glycoside compositions with reduced surface tension STT3A, SIGLEC7, STT3B HSD17B10 473/4885TDP1 1789/4885ALOX15 4388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.